Press Releases OssDsign AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:33 2024-06-07 EDT			5-day change	1st Jan Change
10.14 ^SEK	+2.42%		+6.29%	+26.75%

05-14	Transcript : OssDsign AB, Q1 2024 Earnings Call, May 14, 2024
05-14	OssDsign AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

OssDsign publishes Annual Report 2023	06-04	AQ
5,000 patients treated with OssDsign Catalyst® in the U.S.	05-30	AQ
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB	05-24	AQ
Change of financial calendar	05-16	AQ
OssDsign Q1 - An accelerating turnaround	05-15	AQ
OssDsign: A new beginning – Q1 review	05-15	AQ
OssDsign AB (publ) publishes Q1 2024 interim report	05-14	AQ
OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals	04-29	AQ
OssDsign: Another quarter of triple-digit Catalyst growth expected	04-11	AQ
OssDsign awarded long-term agreement with Premier, Inc.	04-02	AQ
OssDsign: Update after HC seminar and news in the spinal fusion market	03-07	AQ
OssDsign appoints Tom Buckland as Chief Technical Officer	02-29	AQ
OssDsign: Restructuring completed, focus on 2024	02-07	AQ
OssDsign AB (publ) publishes year-end report 2023	02-06	AQ
OssDsign: Right time to fuse the spine	01-29	AQ
12-month data from the clinical study of OssDsign Catalyst™ published in Biomedical Journal of Scientific & Technical Research	01-24	AQ
OssDsign reports exceptional data from the clinical study TOP FUSION	01-09	AQ
OssDsign - Higher-than-expected Q4 preliminary sales	12-07	AQ
OssDsign's revenues for the fourth quarter of 2023 are expected to exceed market estimates	12-06	AQ
SEB Venture Capital has sold its holding in OssDsign	11-30	AQ

No results for this search